FLAURA研究-话题@MedSci - 梅斯（MedSci）

[GetTopicListResponse(id=1940508, encodeId=ca8419405087e, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, objectTitle=再读FLAURA研究：从统计学视角解读OS更新结果, objectType=article, longId=190134, objectId=32e0190134cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32e0190134cf, replyNumber=0, likeNumber=59, createdTime=2021-01-02, rootId=0, userName=jiafufeng@yaho, userId=c30265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32e0190134cf, moduleTitle=再读FLAURA研究：从统计学视角解读OS更新结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=32e0190134cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940509, encodeId=e2b31940509d3, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, objectTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, objectType=article, longId=193345, objectId=a58619334571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a58619334571, replyNumber=0, likeNumber=75, createdTime=2020-12-21, rootId=0, userName=jiafufeng@yaho, userId=c30265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a58619334571, moduleTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a58619334571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940507, encodeId=5abd194050eea, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, objectTitle=基于生存预测模型，对FLAURA研究OS数据进行预测, objectType=article, longId=167063, objectId=921c16e0634a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=921c16e0634a, replyNumber=0, likeNumber=70, createdTime=2019-11-05, rootId=0, userName=jiafufeng@yaho, userId=c30265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=921c16e0634a, moduleTitle=基于生存预测模型，对FLAURA研究OS数据进行预测, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=921c16e0634a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940506, encodeId=f8991940506d5, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, objectTitle=【ESMO Asia】FLAURA研究奠定奥希替尼一线标准治疗地位, objectType=article, longId=121278, objectId=c84a1212e86d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84a1212e86d, replyNumber=0, likeNumber=73, createdTime=2018-06-02, rootId=0, userName=jiafufeng@yaho, userId=c30265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84a1212e86d, moduleTitle=【ESMO Asia】FLAURA研究奠定奥希替尼一线标准治疗地位, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c84a1212e86d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940503, encodeId=74ae1940503ed, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, objectTitle=【WCLC 2017】FLAURA研究伴随诊断结果公布：血浆EGFR突变阳性与组织阳性患者接受奥希替尼一线治疗获益一致, objectType=article, longId=116656, objectId=7181116656ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7181116656ed, replyNumber=0, likeNumber=62, createdTime=2018-04-26, rootId=0, userName=jiafufeng@yaho, userId=c30265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7181116656ed, moduleTitle=【WCLC 2017】FLAURA研究伴随诊断结果公布：血浆EGFR突变阳性与组织阳性患者接受奥希替尼一线治疗获益一致, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7181116656ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940504, encodeId=01591940504f2, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, objectTitle=【ESMO Asia】FLAURA研究：奥希替尼显著降低脑转移患者进展和死亡风险, objectType=article, longId=120687, objectId=615212068e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=615212068e26, replyNumber=0, likeNumber=74, createdTime=2018-09-20, rootId=0, userName=jiafufeng@yaho, userId=c30265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=615212068e26, moduleTitle=【ESMO Asia】FLAURA研究：奥希替尼显著降低脑转移患者进展和死亡风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=615212068e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940505, encodeId=5a3d194050569, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, objectTitle=【ESMO Asia】FLAURA研究：奥希替尼显著延长PFS及ORR, objectType=article, longId=120734, objectId=3f0d120e34d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f0d120e34d1, replyNumber=0, likeNumber=97, createdTime=2018-07-06, rootId=0, userName=jiafufeng@yaho, userId=c30265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f0d120e34d1, moduleTitle=【ESMO Asia】FLAURA研究：奥希替尼显著延长PFS及ORR, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3f0d120e34d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FLAURA研究

2020-05-29

jiafufeng@yaho (审核中...)

前往app查看评论内容

#FLAURA研究#

再读FLAURA研究：从统计学视角解读OS更新结果

2021-01-02

jiafufeng@yaho (审核中...)

前往app查看评论内容

#FLAURA研究#

AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）

2020-12-21

jiafufeng@yaho (审核中...)

前往app查看评论内容

#FLAURA研究#

基于生存预测模型，对FLAURA研究OS数据进行预测

2019-11-05

jiafufeng@yaho (审核中...)

前往app查看评论内容

#FLAURA研究#

【ESMO Asia】FLAURA研究奠定奥希替尼一线标准治疗地位

2018-06-02

jiafufeng@yaho (审核中...)

前往app查看评论内容

#FLAURA研究#

【WCLC 2017】FLAURA研究伴随诊断结果公布：血浆EGFR突变阳性与组织阳性患者接受奥希替尼一线治疗获益一致

2018-04-26

jiafufeng@yaho (审核中...)

前往app查看评论内容

#FLAURA研究#

【ESMO Asia】FLAURA研究：奥希替尼显著降低脑转移患者进展和死亡风险

2018-09-20

jiafufeng@yaho (审核中...)

前往app查看评论内容

#FLAURA研究#

【ESMO Asia】FLAURA研究：奥希替尼显著延长PFS及ORR

2018-07-06

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

#FLAURA研究#

科室

工具

服务